• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Respir Investig . Impact of the COVID-19 pandemic on acute exacerbation of idiopathic pulmonary fibrosis: a nationwide observational study in Japan

tetano

Editor, Senior Moderator
Respir Investig


. 2025 Nov 17;64(1):101326.
doi: 10.1016/j.resinv.2025.11.005. Online ahead of print. Impact of the COVID-19 pandemic on acute exacerbation of idiopathic pulmonary fibrosis: a nationwide observational study in Japan

Yuichi Ohteru[SUP] 1 [/SUP], Tomoyuki Kakugawa[SUP] 2 [/SUP], Masahiro Kakugawa[SUP] 3 [/SUP], Tsunahiko Hirano[SUP] 4 [/SUP], Kazuto Matsunaga[SUP] 4 [/SUP]



Affiliations
Abstract

Background: The coronavirus disease 2019 (COVID-19) pandemic and associated infection control measures drastically reduced respiratory infections worldwide. This unique context facilitated a natural investigation of the role of respiratory infections in triggering acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF). The aim of this study was to evaluate changes in AE-IPF incidence, seasonality, and prognosis before and during the pandemic using a nationwide Japanese database.
Methods: This retrospective cohort study was based on hospitalization data from April 1, 2018 to March 31, 2022. Pandemic-related changes in AE-IPF incidence, seasonal trends, and outcomes were assessed with respect to the pre-pandemic period using mixed-design analysis of variance and Kaplan-Meier survival analysis. For comparison, similar changes in chronic obstructive pulmonary disease (COPD) exacerbation were examined using the same methods.
Results: Despite reduced respiratory infections, AE-IPF incidence did not decrease during the pandemic. While the typical winter surge in respiratory infections disappeared during the pandemic, the seasonal increase in AE-IPF incidence during winter persisted. However, the incidence of COPD exacerbations decreased significantly, and the seasonality of exacerbations shifted during the pandemic.
Conclusions: The findings of this study question the prior assumption that respiratory infections are key contributors to AE-IPF. While respiratory infections may play a role in some cases, our results suggest that, at least for pre-pandemic respiratory infections, their overall contribution may be less substantial than that previously assumed. This underscores the need to reconsider the pathogenesis of AE-IPF and explore noninfectious mechanisms with regard to its management.

Keywords: Acute exacerbation; Coronavirus disease 2019; Idiopathic pulmonary fibrosis; Pandemic; Respiratory infection.

 
Back
Top